Aperture Therapeutics Unveils Groundbreaking ALS Treatment with MMP9 Antisense Oligonucleotide Aperture Therapeutics announces its first-class MMP9 antisense oligonucleotide program aimed at treating ALS by targeting neuroinflammation and degeneration.

Aperture Therapeutics Unveils Groundbreaking ALS Treatment with MMP9 Antisense Oligonucleotide #USA #ALS #San_Carlos #Aperture_Therapeutics #MMP9

Aperture Therapeutics Unveils Innovative Therapy for Neurodegenerative Diseases Targeting CD33 Aperture Therapeutics has announced the nomination of APRTX-001, a promising therapy targeting CD33, aiming to treat Frontotemporal Dementia and ALS, with broader applications in Alzheimer’s Disease.

Aperture Therapeutics Unveils Innovative Therapy for Neurodegenerative Diseases Targeting CD33 #USA #San_Carlos #Aperture_Therapeutics #APRTX-001 #CD33